| . | Resistant hypertension (n = 1406) . | Uncontrolled hypertension (n = 581) . | Controlled hypertension (n = 3546) . | P-value . | With MRA (n = 502) . | Without MRA (n = 904) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP (mmHg) | 149.6 | (9.5) | 147.1 | (7.7) | 125.9 | (8.3) | NA | 149.0 | (9.2) | 149.9 | (9.7) |
| HR (b.p.m.) | 69.4 | (11.6) | 69.6 | (11.7) | 70.7 | (11.9) | .0010 | 70.5 | (11.8) | 68.8 | (11.4) |
| Sex | .2059 | ||||||||||
| Female | 655 | (46.6) | 255 | (43.9) | 1555 | (43.9) | 216 | (43.0) | 439 | (48.6) | |
| Male | 751 | (53.4) | 326 | (56.1) | 1991 | (56.1) | 286 | (57.0) | 465 | (51.4) | |
| Age (years) | 72.3 | (9.2) | 73.9 | (8.4) | 71.6 | (9.5) | <.0001 | 70.4 | (9.5) | 73.3 | (8.8) |
| Race | <.0001 | ||||||||||
| White | 1087 | (77.3) | 415 | (71.4) | 2731 | (77.0) | 385 | (76.7) | 702 | (77.7) | |
| Black/African-American | 90 | (6.4) | 23 | (4.0) | 124 | (3.5) | 26 | (5.2) | 64 | (7.1) | |
| Asian | 130 | (9.2) | 109 | (18.8) | 489 | (13.8) | 58 | (11.6) | 72 | (8.0) | |
| Other incl. mixed | 99 | (7.0) | 34 | (5.9) | 200 | (5.6) | 33 | (6.6) | 66 | (7.3) | |
| Region | <.0001 | ||||||||||
| North America | 138 | (9.8) | 82 | (14.1) | 417 | (11.8) | 26 | (5.2) | 112 | (12.4) | |
| Latin America | 322 | (22.9) | 115 | (19.8) | 950 | (26.8) | 138 | (27.5) | 184 | (20.4) | |
| Europe | 748 | (53.2) | 254 | (43.7) | 1561 | (44.0) | 263 | (52.4) | 485 | (53.7) | |
| Asia | 112 | (8.0) | 81 | (13.9) | 405 | (11.4) | 52 | (10.4) | 60 | (6.6) | |
| Other | 86 | (6.1) | 49 | (8.4) | 213 | (6.0) | 23 | (4.6) | 63 | (7.0) | |
| LVEF (%) | 54.4 | (8.8) | 55.5 | (8.5) | 54.1 | (8.8) | .0020 | 53.0 | (8.7) | 55.3 | (8.7) |
| NT-proBNP (pg/mL) | 933 | (482–1685) | 919 | (499–1571) | 979 | (500–1739) | .5484* | 905 | (470–1677) | 946 | (486–1686) |
| HS troponin T (ng/L) | 18.7 | (12.7–27.6) | 17.2 | (11.5–26.1) | 17.4 | (11.5–26.6) | .0168* | 18.4 | (12.0–26.3) | 18.7 | (13.0–28.5) |
| Weight (kg) | 84.9 | (19.5) | 78.9 | (18.9) | 81.6 | (19.3) | <.0001 | 85.2 | (19.5) | 84.7 | (19.6) |
| BMI (kg/m2) | 30.9 | (6.0) | 28.8 | (5.8) | 29.7 | (5.8) | <.0001 | 30.9 | (6.0) | 31.0 | (6.0) |
| eGFR (mL/min/1.73 m2) | 60.1 | (19.8) | 60.9 | (18.8) | 60.9 | (19.8) | .4423 | 62.8 | (19.7) | 58.6 | (19.7) |
| <60 | 714 | (50.8) | 277 | (47.7) | 1767 | (49.8) | .4524 | 232 | (46.2) | 482 | (53.3) |
| UACR (mg/g) | <.0001 | ||||||||||
| <30 | 684 | (48.6) | 312 | (53.7) | 2178 | (61.4) | 258 | (51.4) | 426 | (47.1) | |
| 30–300 | 457 | (32.5) | 190 | (32.7) | 1077 | (30.4) | 153 | (30.5) | 304 | (33.6) | |
| >300 | 261 | (18.6) | 74 | (12.7) | 276 | (7.8) | 88 | (17.5) | 173 | (19.1) | |
| Haemoglobin (g/dL) | 13.3 | (1.6) | 13.4 | (1.6) | 13.3 | (1.6) | .5425 | 13.5 | (1.6) | 13.2 | (1.6) |
| History of Afib/flutter | 686 | (48.8) | 283 | (48.7) | 1896 | (53.5) | .0028 | 244 | (48.6) | 442 | (48.9) |
| History of HHF | 324 | (23.0) | 100 | (17.2) | 821 | (23.2) | .0055 | 146 | (29.1) | 178 | (19.7) |
| NYHA Class I/II | 1106 | (78.7) | 487 | (83.8) | 2948 | (83.1) | .0005 | 400 | (79.7) | 706 | (78.1) |
| NYHA Class III/IV | 300 | (21.3) | 94 | (16.2) | 598 | (16.9) | 102 | (20.3) | 198 | (21.9) | |
| Cause of HF | .6550 | ||||||||||
| Ischsemic | 509 | (36.2) | 215 | (37.0) | 1251 | (35.3) | 211 | (42.0) | 298 | (33.0 | |
| Non-ischaemic | 897 | (63.8) | 366 | (63.0) | 2294 | (64.7) | 291 | (58.0) | 606 | (67.0) | |
| DM | 813 | (57.8) | 247 | (42.5) | 1684 | (47.5) | <.0001 | 302 | (60.2) | 511 | (56.5) |
| ACEi/ARB/ARNi | 1331 | (94.7) | 345 | (59.4) | 2809 | (79.2) | <.0001 | 483 | (96.2) | 848 | (93.8) |
| Beta-blockers | 1312 | (93.3) | 376 | (64.7) | 3077 | (86.8) | <.0001 | 474 | (94.4) | 838 | (92.7) |
| Diuretics (other than MRA) | 1309 | (93.1) | 260 | (44.8) | 2863 | (80.7) | <.0001 | 405 | (80.7) | 904 | (100.0) |
| MRA | 502 | (35.7) | 99 | (17.0) | 1409 | (39.7) | <.0001 | 502 | (100.0) | 0 | |
| . | Resistant hypertension (n = 1406) . | Uncontrolled hypertension (n = 581) . | Controlled hypertension (n = 3546) . | P-value . | With MRA (n = 502) . | Without MRA (n = 904) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP (mmHg) | 149.6 | (9.5) | 147.1 | (7.7) | 125.9 | (8.3) | NA | 149.0 | (9.2) | 149.9 | (9.7) |
| HR (b.p.m.) | 69.4 | (11.6) | 69.6 | (11.7) | 70.7 | (11.9) | .0010 | 70.5 | (11.8) | 68.8 | (11.4) |
| Sex | .2059 | ||||||||||
| Female | 655 | (46.6) | 255 | (43.9) | 1555 | (43.9) | 216 | (43.0) | 439 | (48.6) | |
| Male | 751 | (53.4) | 326 | (56.1) | 1991 | (56.1) | 286 | (57.0) | 465 | (51.4) | |
| Age (years) | 72.3 | (9.2) | 73.9 | (8.4) | 71.6 | (9.5) | <.0001 | 70.4 | (9.5) | 73.3 | (8.8) |
| Race | <.0001 | ||||||||||
| White | 1087 | (77.3) | 415 | (71.4) | 2731 | (77.0) | 385 | (76.7) | 702 | (77.7) | |
| Black/African-American | 90 | (6.4) | 23 | (4.0) | 124 | (3.5) | 26 | (5.2) | 64 | (7.1) | |
| Asian | 130 | (9.2) | 109 | (18.8) | 489 | (13.8) | 58 | (11.6) | 72 | (8.0) | |
| Other incl. mixed | 99 | (7.0) | 34 | (5.9) | 200 | (5.6) | 33 | (6.6) | 66 | (7.3) | |
| Region | <.0001 | ||||||||||
| North America | 138 | (9.8) | 82 | (14.1) | 417 | (11.8) | 26 | (5.2) | 112 | (12.4) | |
| Latin America | 322 | (22.9) | 115 | (19.8) | 950 | (26.8) | 138 | (27.5) | 184 | (20.4) | |
| Europe | 748 | (53.2) | 254 | (43.7) | 1561 | (44.0) | 263 | (52.4) | 485 | (53.7) | |
| Asia | 112 | (8.0) | 81 | (13.9) | 405 | (11.4) | 52 | (10.4) | 60 | (6.6) | |
| Other | 86 | (6.1) | 49 | (8.4) | 213 | (6.0) | 23 | (4.6) | 63 | (7.0) | |
| LVEF (%) | 54.4 | (8.8) | 55.5 | (8.5) | 54.1 | (8.8) | .0020 | 53.0 | (8.7) | 55.3 | (8.7) |
| NT-proBNP (pg/mL) | 933 | (482–1685) | 919 | (499–1571) | 979 | (500–1739) | .5484* | 905 | (470–1677) | 946 | (486–1686) |
| HS troponin T (ng/L) | 18.7 | (12.7–27.6) | 17.2 | (11.5–26.1) | 17.4 | (11.5–26.6) | .0168* | 18.4 | (12.0–26.3) | 18.7 | (13.0–28.5) |
| Weight (kg) | 84.9 | (19.5) | 78.9 | (18.9) | 81.6 | (19.3) | <.0001 | 85.2 | (19.5) | 84.7 | (19.6) |
| BMI (kg/m2) | 30.9 | (6.0) | 28.8 | (5.8) | 29.7 | (5.8) | <.0001 | 30.9 | (6.0) | 31.0 | (6.0) |
| eGFR (mL/min/1.73 m2) | 60.1 | (19.8) | 60.9 | (18.8) | 60.9 | (19.8) | .4423 | 62.8 | (19.7) | 58.6 | (19.7) |
| <60 | 714 | (50.8) | 277 | (47.7) | 1767 | (49.8) | .4524 | 232 | (46.2) | 482 | (53.3) |
| UACR (mg/g) | <.0001 | ||||||||||
| <30 | 684 | (48.6) | 312 | (53.7) | 2178 | (61.4) | 258 | (51.4) | 426 | (47.1) | |
| 30–300 | 457 | (32.5) | 190 | (32.7) | 1077 | (30.4) | 153 | (30.5) | 304 | (33.6) | |
| >300 | 261 | (18.6) | 74 | (12.7) | 276 | (7.8) | 88 | (17.5) | 173 | (19.1) | |
| Haemoglobin (g/dL) | 13.3 | (1.6) | 13.4 | (1.6) | 13.3 | (1.6) | .5425 | 13.5 | (1.6) | 13.2 | (1.6) |
| History of Afib/flutter | 686 | (48.8) | 283 | (48.7) | 1896 | (53.5) | .0028 | 244 | (48.6) | 442 | (48.9) |
| History of HHF | 324 | (23.0) | 100 | (17.2) | 821 | (23.2) | .0055 | 146 | (29.1) | 178 | (19.7) |
| NYHA Class I/II | 1106 | (78.7) | 487 | (83.8) | 2948 | (83.1) | .0005 | 400 | (79.7) | 706 | (78.1) |
| NYHA Class III/IV | 300 | (21.3) | 94 | (16.2) | 598 | (16.9) | 102 | (20.3) | 198 | (21.9) | |
| Cause of HF | .6550 | ||||||||||
| Ischsemic | 509 | (36.2) | 215 | (37.0) | 1251 | (35.3) | 211 | (42.0) | 298 | (33.0 | |
| Non-ischaemic | 897 | (63.8) | 366 | (63.0) | 2294 | (64.7) | 291 | (58.0) | 606 | (67.0) | |
| DM | 813 | (57.8) | 247 | (42.5) | 1684 | (47.5) | <.0001 | 302 | (60.2) | 511 | (56.5) |
| ACEi/ARB/ARNi | 1331 | (94.7) | 345 | (59.4) | 2809 | (79.2) | <.0001 | 483 | (96.2) | 848 | (93.8) |
| Beta-blockers | 1312 | (93.3) | 376 | (64.7) | 3077 | (86.8) | <.0001 | 474 | (94.4) | 838 | (92.7) |
| Diuretics (other than MRA) | 1309 | (93.1) | 260 | (44.8) | 2863 | (80.7) | <.0001 | 405 | (80.7) | 904 | (100.0) |
| MRA | 502 | (35.7) | 99 | (17.0) | 1409 | (39.7) | <.0001 | 502 | (100.0) | 0 | |
Statistical tests were done with ANOVA for continuous variables and χ2 for categorical variables. *N-terminal pro-B-type natriuretic peptide and HB troponin were based on log transformed results.
Data are presented as mean (SD) or median (Q1–Q3).
ACEi, angiotensin-converting enzyme inhibitor; Afib, atrial fibrillation; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HF, heart failure; HHF, hospitalization for heart failure; HR, heart rate; HS, high sensitive; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; UACR, urine albumin–creatinine ratio.
| . | Resistant hypertension (n = 1406) . | Uncontrolled hypertension (n = 581) . | Controlled hypertension (n = 3546) . | P-value . | With MRA (n = 502) . | Without MRA (n = 904) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP (mmHg) | 149.6 | (9.5) | 147.1 | (7.7) | 125.9 | (8.3) | NA | 149.0 | (9.2) | 149.9 | (9.7) |
| HR (b.p.m.) | 69.4 | (11.6) | 69.6 | (11.7) | 70.7 | (11.9) | .0010 | 70.5 | (11.8) | 68.8 | (11.4) |
| Sex | .2059 | ||||||||||
| Female | 655 | (46.6) | 255 | (43.9) | 1555 | (43.9) | 216 | (43.0) | 439 | (48.6) | |
| Male | 751 | (53.4) | 326 | (56.1) | 1991 | (56.1) | 286 | (57.0) | 465 | (51.4) | |
| Age (years) | 72.3 | (9.2) | 73.9 | (8.4) | 71.6 | (9.5) | <.0001 | 70.4 | (9.5) | 73.3 | (8.8) |
| Race | <.0001 | ||||||||||
| White | 1087 | (77.3) | 415 | (71.4) | 2731 | (77.0) | 385 | (76.7) | 702 | (77.7) | |
| Black/African-American | 90 | (6.4) | 23 | (4.0) | 124 | (3.5) | 26 | (5.2) | 64 | (7.1) | |
| Asian | 130 | (9.2) | 109 | (18.8) | 489 | (13.8) | 58 | (11.6) | 72 | (8.0) | |
| Other incl. mixed | 99 | (7.0) | 34 | (5.9) | 200 | (5.6) | 33 | (6.6) | 66 | (7.3) | |
| Region | <.0001 | ||||||||||
| North America | 138 | (9.8) | 82 | (14.1) | 417 | (11.8) | 26 | (5.2) | 112 | (12.4) | |
| Latin America | 322 | (22.9) | 115 | (19.8) | 950 | (26.8) | 138 | (27.5) | 184 | (20.4) | |
| Europe | 748 | (53.2) | 254 | (43.7) | 1561 | (44.0) | 263 | (52.4) | 485 | (53.7) | |
| Asia | 112 | (8.0) | 81 | (13.9) | 405 | (11.4) | 52 | (10.4) | 60 | (6.6) | |
| Other | 86 | (6.1) | 49 | (8.4) | 213 | (6.0) | 23 | (4.6) | 63 | (7.0) | |
| LVEF (%) | 54.4 | (8.8) | 55.5 | (8.5) | 54.1 | (8.8) | .0020 | 53.0 | (8.7) | 55.3 | (8.7) |
| NT-proBNP (pg/mL) | 933 | (482–1685) | 919 | (499–1571) | 979 | (500–1739) | .5484* | 905 | (470–1677) | 946 | (486–1686) |
| HS troponin T (ng/L) | 18.7 | (12.7–27.6) | 17.2 | (11.5–26.1) | 17.4 | (11.5–26.6) | .0168* | 18.4 | (12.0–26.3) | 18.7 | (13.0–28.5) |
| Weight (kg) | 84.9 | (19.5) | 78.9 | (18.9) | 81.6 | (19.3) | <.0001 | 85.2 | (19.5) | 84.7 | (19.6) |
| BMI (kg/m2) | 30.9 | (6.0) | 28.8 | (5.8) | 29.7 | (5.8) | <.0001 | 30.9 | (6.0) | 31.0 | (6.0) |
| eGFR (mL/min/1.73 m2) | 60.1 | (19.8) | 60.9 | (18.8) | 60.9 | (19.8) | .4423 | 62.8 | (19.7) | 58.6 | (19.7) |
| <60 | 714 | (50.8) | 277 | (47.7) | 1767 | (49.8) | .4524 | 232 | (46.2) | 482 | (53.3) |
| UACR (mg/g) | <.0001 | ||||||||||
| <30 | 684 | (48.6) | 312 | (53.7) | 2178 | (61.4) | 258 | (51.4) | 426 | (47.1) | |
| 30–300 | 457 | (32.5) | 190 | (32.7) | 1077 | (30.4) | 153 | (30.5) | 304 | (33.6) | |
| >300 | 261 | (18.6) | 74 | (12.7) | 276 | (7.8) | 88 | (17.5) | 173 | (19.1) | |
| Haemoglobin (g/dL) | 13.3 | (1.6) | 13.4 | (1.6) | 13.3 | (1.6) | .5425 | 13.5 | (1.6) | 13.2 | (1.6) |
| History of Afib/flutter | 686 | (48.8) | 283 | (48.7) | 1896 | (53.5) | .0028 | 244 | (48.6) | 442 | (48.9) |
| History of HHF | 324 | (23.0) | 100 | (17.2) | 821 | (23.2) | .0055 | 146 | (29.1) | 178 | (19.7) |
| NYHA Class I/II | 1106 | (78.7) | 487 | (83.8) | 2948 | (83.1) | .0005 | 400 | (79.7) | 706 | (78.1) |
| NYHA Class III/IV | 300 | (21.3) | 94 | (16.2) | 598 | (16.9) | 102 | (20.3) | 198 | (21.9) | |
| Cause of HF | .6550 | ||||||||||
| Ischsemic | 509 | (36.2) | 215 | (37.0) | 1251 | (35.3) | 211 | (42.0) | 298 | (33.0 | |
| Non-ischaemic | 897 | (63.8) | 366 | (63.0) | 2294 | (64.7) | 291 | (58.0) | 606 | (67.0) | |
| DM | 813 | (57.8) | 247 | (42.5) | 1684 | (47.5) | <.0001 | 302 | (60.2) | 511 | (56.5) |
| ACEi/ARB/ARNi | 1331 | (94.7) | 345 | (59.4) | 2809 | (79.2) | <.0001 | 483 | (96.2) | 848 | (93.8) |
| Beta-blockers | 1312 | (93.3) | 376 | (64.7) | 3077 | (86.8) | <.0001 | 474 | (94.4) | 838 | (92.7) |
| Diuretics (other than MRA) | 1309 | (93.1) | 260 | (44.8) | 2863 | (80.7) | <.0001 | 405 | (80.7) | 904 | (100.0) |
| MRA | 502 | (35.7) | 99 | (17.0) | 1409 | (39.7) | <.0001 | 502 | (100.0) | 0 | |
| . | Resistant hypertension (n = 1406) . | Uncontrolled hypertension (n = 581) . | Controlled hypertension (n = 3546) . | P-value . | With MRA (n = 502) . | Without MRA (n = 904) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP (mmHg) | 149.6 | (9.5) | 147.1 | (7.7) | 125.9 | (8.3) | NA | 149.0 | (9.2) | 149.9 | (9.7) |
| HR (b.p.m.) | 69.4 | (11.6) | 69.6 | (11.7) | 70.7 | (11.9) | .0010 | 70.5 | (11.8) | 68.8 | (11.4) |
| Sex | .2059 | ||||||||||
| Female | 655 | (46.6) | 255 | (43.9) | 1555 | (43.9) | 216 | (43.0) | 439 | (48.6) | |
| Male | 751 | (53.4) | 326 | (56.1) | 1991 | (56.1) | 286 | (57.0) | 465 | (51.4) | |
| Age (years) | 72.3 | (9.2) | 73.9 | (8.4) | 71.6 | (9.5) | <.0001 | 70.4 | (9.5) | 73.3 | (8.8) |
| Race | <.0001 | ||||||||||
| White | 1087 | (77.3) | 415 | (71.4) | 2731 | (77.0) | 385 | (76.7) | 702 | (77.7) | |
| Black/African-American | 90 | (6.4) | 23 | (4.0) | 124 | (3.5) | 26 | (5.2) | 64 | (7.1) | |
| Asian | 130 | (9.2) | 109 | (18.8) | 489 | (13.8) | 58 | (11.6) | 72 | (8.0) | |
| Other incl. mixed | 99 | (7.0) | 34 | (5.9) | 200 | (5.6) | 33 | (6.6) | 66 | (7.3) | |
| Region | <.0001 | ||||||||||
| North America | 138 | (9.8) | 82 | (14.1) | 417 | (11.8) | 26 | (5.2) | 112 | (12.4) | |
| Latin America | 322 | (22.9) | 115 | (19.8) | 950 | (26.8) | 138 | (27.5) | 184 | (20.4) | |
| Europe | 748 | (53.2) | 254 | (43.7) | 1561 | (44.0) | 263 | (52.4) | 485 | (53.7) | |
| Asia | 112 | (8.0) | 81 | (13.9) | 405 | (11.4) | 52 | (10.4) | 60 | (6.6) | |
| Other | 86 | (6.1) | 49 | (8.4) | 213 | (6.0) | 23 | (4.6) | 63 | (7.0) | |
| LVEF (%) | 54.4 | (8.8) | 55.5 | (8.5) | 54.1 | (8.8) | .0020 | 53.0 | (8.7) | 55.3 | (8.7) |
| NT-proBNP (pg/mL) | 933 | (482–1685) | 919 | (499–1571) | 979 | (500–1739) | .5484* | 905 | (470–1677) | 946 | (486–1686) |
| HS troponin T (ng/L) | 18.7 | (12.7–27.6) | 17.2 | (11.5–26.1) | 17.4 | (11.5–26.6) | .0168* | 18.4 | (12.0–26.3) | 18.7 | (13.0–28.5) |
| Weight (kg) | 84.9 | (19.5) | 78.9 | (18.9) | 81.6 | (19.3) | <.0001 | 85.2 | (19.5) | 84.7 | (19.6) |
| BMI (kg/m2) | 30.9 | (6.0) | 28.8 | (5.8) | 29.7 | (5.8) | <.0001 | 30.9 | (6.0) | 31.0 | (6.0) |
| eGFR (mL/min/1.73 m2) | 60.1 | (19.8) | 60.9 | (18.8) | 60.9 | (19.8) | .4423 | 62.8 | (19.7) | 58.6 | (19.7) |
| <60 | 714 | (50.8) | 277 | (47.7) | 1767 | (49.8) | .4524 | 232 | (46.2) | 482 | (53.3) |
| UACR (mg/g) | <.0001 | ||||||||||
| <30 | 684 | (48.6) | 312 | (53.7) | 2178 | (61.4) | 258 | (51.4) | 426 | (47.1) | |
| 30–300 | 457 | (32.5) | 190 | (32.7) | 1077 | (30.4) | 153 | (30.5) | 304 | (33.6) | |
| >300 | 261 | (18.6) | 74 | (12.7) | 276 | (7.8) | 88 | (17.5) | 173 | (19.1) | |
| Haemoglobin (g/dL) | 13.3 | (1.6) | 13.4 | (1.6) | 13.3 | (1.6) | .5425 | 13.5 | (1.6) | 13.2 | (1.6) |
| History of Afib/flutter | 686 | (48.8) | 283 | (48.7) | 1896 | (53.5) | .0028 | 244 | (48.6) | 442 | (48.9) |
| History of HHF | 324 | (23.0) | 100 | (17.2) | 821 | (23.2) | .0055 | 146 | (29.1) | 178 | (19.7) |
| NYHA Class I/II | 1106 | (78.7) | 487 | (83.8) | 2948 | (83.1) | .0005 | 400 | (79.7) | 706 | (78.1) |
| NYHA Class III/IV | 300 | (21.3) | 94 | (16.2) | 598 | (16.9) | 102 | (20.3) | 198 | (21.9) | |
| Cause of HF | .6550 | ||||||||||
| Ischsemic | 509 | (36.2) | 215 | (37.0) | 1251 | (35.3) | 211 | (42.0) | 298 | (33.0 | |
| Non-ischaemic | 897 | (63.8) | 366 | (63.0) | 2294 | (64.7) | 291 | (58.0) | 606 | (67.0) | |
| DM | 813 | (57.8) | 247 | (42.5) | 1684 | (47.5) | <.0001 | 302 | (60.2) | 511 | (56.5) |
| ACEi/ARB/ARNi | 1331 | (94.7) | 345 | (59.4) | 2809 | (79.2) | <.0001 | 483 | (96.2) | 848 | (93.8) |
| Beta-blockers | 1312 | (93.3) | 376 | (64.7) | 3077 | (86.8) | <.0001 | 474 | (94.4) | 838 | (92.7) |
| Diuretics (other than MRA) | 1309 | (93.1) | 260 | (44.8) | 2863 | (80.7) | <.0001 | 405 | (80.7) | 904 | (100.0) |
| MRA | 502 | (35.7) | 99 | (17.0) | 1409 | (39.7) | <.0001 | 502 | (100.0) | 0 | |
Statistical tests were done with ANOVA for continuous variables and χ2 for categorical variables. *N-terminal pro-B-type natriuretic peptide and HB troponin were based on log transformed results.
Data are presented as mean (SD) or median (Q1–Q3).
ACEi, angiotensin-converting enzyme inhibitor; Afib, atrial fibrillation; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HF, heart failure; HHF, hospitalization for heart failure; HR, heart rate; HS, high sensitive; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; UACR, urine albumin–creatinine ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
